All In Biotech

Drug Trial Radar · NCT07668375

Outcome of Treatment With Botulinum toxinA in Patients With Temporomandibular Myofascial Pain

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Jan 2, 2026

Primary completion

Apr 1, 2026

Study completion Apr 1, 2026

Sponsor

Lead sponsor
PAEC General Hospital, IslamabadAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose: The aim of this study is to investigate the effectiveness and patient reported outcomes (interincisal distance and temporomandibular myofascial pain) of treatment with intramuscularly administered BTX-A vs N/S in patients with temporomandibular myofascial pain. OBJECTIVES: To determine the outcome of treatment with botulinum toxin-A vs N/S in patients with temporomandibular myofascial pain.

Conditions

  • Myofascial Pain - Dysfunction Syndrome of TMJ

Interventions

  • Botulinum Toxin-A (Botulax - letibotulinumtoxinA)Drug

    In this study, intramuscular injection of Botulinum Toxin-A (50-100 units) would be administered to the patient using a 1 mL insulin syringe with a 26G needle at a dilution of 10 U/mL in normal saline. Injections would be given at 5 sites: 3 in the masseter muscle and 2 in the temporalis muscle, based on the patient's side of complaint (unilateral or bilateral). Topical lidocaine 5% cream would be applied before injection. The injection aims to reduce jaw muscle pain and increase interincisal mouth opening, allowing patients to resume normal daily activities without delay.

  • Normal SalineDrug

    Intramuscular injection of normal saline (N/S) 1 mL would be administered at the same sites (masseter and temporalis muscles) as a placebo comparator. Normal saline injection would not be expected to significantly reduce pain intensity or increase interincisal mouth opening compared to BTX-A.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of post-injection pain in patients diagnosed with Temporomandibular Myofascial PainTime frame: From enrolment to 4, 8, and 12 weeks post-injection
  2. Measurement of Interincisal mouth opening in patients diagnosed with Temporomandibular Myofascial Pain.Time frame: From enrolment to 4, 8, and 12 weeks post-injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PAEC General Hospital, Islamabad

    Islamabad, Islamabad, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.